Should patients on dialysis take finasteride?

Finasteride Use in Dialysis Patients

Finasteride can be safely used in dialysis patients without dose adjustment, as the drug is primarily metabolized by the liver and not significantly cleared by the kidneys. 1

Pharmacokinetic Considerations in Renal Impairment

The FDA label provides clear guidance on finasteride use in renal impairment 1:

• No dosage adjustment is necessary in patients with renal impairment, including those on dialysis
• Studies in patients with chronic renal impairment (creatinine clearances 9.0-55 mL/min) showed that AUC, maximum plasma concentration, half-life, and protein binding were similar to healthy volunteers
• Urinary excretion of metabolites decreases in renal impairment, but this is compensated by increased fecal excretion
• Plasma concentrations of metabolites are 60% higher in renal impairment, but finasteride has been well tolerated at doses up to 80 mg/day for 12 weeks in BPH patients with normal renal function

Key Metabolic Pathway

Finasteride is extensively metabolized in the liver via cytochrome P450 3A4, not renally cleared 1. This hepatic metabolism means dialysis patients can use standard dosing without concern for drug accumulation.

Clinical Indications and Efficacy

If the dialysis patient has appropriate indications, finasteride remains effective 2, 3:

For BPH/LUTS:

• Only use if prostate volume >30cc or PSA >1.5 ng/mL 3
• Reduces risk of acute urinary retention by 67% and BPH-related surgery by 64% 2
• Expect 3-4 point improvement in symptom scores, but onset is slower than alpha-blockers 3

Critical caveat: Finasteride is not appropriate for men without prostatic enlargement 2

Important Safety Considerations in Dialysis Patients

Metabolite Accumulation

While plasma metabolite concentrations are 60% higher in renal impairment 1, this has not translated to increased toxicity in clinical studies. However, caution is warranted given emerging concerns about long-term metabolic effects.

Emerging Renal Concerns

Recent animal studies raise potential red flags 4, 5:

• Finasteride caused morphological and functional kidney damage in rats, including reduced glomerular number (26.8% reduction) and increased serum creatinine 4
• DHT deficiency may impair kidney physiology through altered androgen receptor expression and tubular fibrosis 5

Clinical interpretation: While these are animal studies and the FDA label supports use in renal impairment based on human pharmacokinetic data, extra vigilance is prudent in dialysis patients who already have compromised renal function. Monitor for any signs of clinical deterioration.

Sexual and Metabolic Side Effects

Standard finasteride side effects apply 3, 6:

• Sexual dysfunction (decreased libido, erectile dysfunction, ejaculatory dysfunction)
• Potential post-finasteride syndrome with persistent symptoms after discontinuation
• Possible metabolic effects including insulin resistance and fatty liver disease 7

Quality of life consideration: Dialysis patients already face significant disease burden. Weigh the 10-15% risk of sexual side effects against the benefits of preventing urinary retention or surgery.

Practical Algorithm for Dialysis Patients

1. Confirm appropriate indication:

   • Document prostate volume >30cc (via TRUS or imaging) OR PSA >1.5 ng/mL
   • If no prostatic enlargement → do not prescribe finasteride 2

2. Dosing:

   • Use standard dose: 5 mg daily for BPH (1 mg for alopecia)
   • No dose adjustment needed for dialysis 1

3. Monitoring:

   • PSA levels: After 1 year, double the measured PSA value to account for 50% reduction by finasteride 3
   • Watch for sexual side effects (counsel patient preemptively)
   • Monitor liver function if any hepatic abnormalities present 1
   • Consider closer monitoring of overall clinical status given animal data on renal effects

4. Hepatic function:

   • Exercise caution if liver function abnormalities exist, as finasteride is hepatically metabolized 1

Bottom Line

Finasteride is pharmacokinetically safe in dialysis patients and requires no dose adjustment. The primary consideration is ensuring appropriate indication (enlarged prostate) rather than renal dosing concerns. However, given the patient's already compromised health status and emerging data on potential renal effects, carefully weigh benefits against risks and maintain heightened clinical surveillance.